Using Empathy and Medicine
Professor of medicine, surgery and molecular and medical pharmacology at the University of California Los Angeles and a director of the Parker Institute for Cancer Immunotherapy at U.C.L.A.
In January 2012, R. Stewart Scannell’s doctor flatly informed him that melanoma had spread throughout his body and into his brain and he had just months to live. “There was no sympathy, no empathy, no nothing,” Mr. Scannell said.
Mr. Scannell, who was 64 at the time, didn’t want to give up. He tracked down a clinical trial at U.C.L.A., and turned up in the office of Dr. Antoni Ribas.
The tone was so different, said Mr. Scannell, who has flown from his home outside Oklahoma City to Los Angeles for treatment every three weeks since, a total of 105 times. He now considers Dr. Ribas a friend.
Dr. Ribas is a patient favorite not only because of his bedside manner. He has also saved their lives.
For the last 17 years, Dr. Ribas, 52, has been at the forefront of a revolution in treating cancer, by turning the patient’s own immune system against it.
In 2001, when cancer immunotherapy was mostly dismissed as hopeless, Dr. Ribas began one of the first clinical trials to test it. His first patient to respond is still alive. He later led the clinical development of an immunotherapy drug called Keytruda, which has since been approved to treat metastatic melanoma, lung cancer and other tumors.
Mr. Scannell’s tumors have either stopped growing or shrunk for the last six years. He has had no obvious side effects, and he is back on the golf course a day or two after each treatment, he said.
Most patients don’t get such fabulous results, however, and half of those with metastatic melanoma still die within five years. So Dr. Ribas, a fourth-generation physician who spends two days a week seeing patients and the rest in his lab, has been studying other ways to manipulate the immune system to fight cancer.
“It’s always nice to see responders, but I see the ones who don’t respond, too,” Dr. Ribas said. “It’s not the time to slow down. It’s time to do more.”
How We Picked Our Visionaries
People love lists.
We want to check out the best places to travel, catch up with the best inventions of the last 100 years, be in the know about the best-dressed people, the best books, the best schools. And on and on.
Of course, there is a risk to listmaking. Maybe your choices won’t hold up over the years. Maybe the best book of decades ago seems not so great today.
With the listmaking fervor and its risks in mind, we searched for people who would fit our criteria for visionaries. They had to be people who are forward-looking, working on exciting projects, helping others or taking a new direction. We wanted diversity in gender, race and ethnic background.
We assigned writers who are knowledgeable about the subjects we deemed most important. And we limited the list to 30.
Narrowing down the numbers was a huge challenge. And that’s a good problem to have. It means there are a lot of people out there who are following their visions.
We hope this inspires you to follow yours.